Drugs / HD-003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02378194 | Jan 2010 → Mar 2013 | chronic renal failure syndrome | Hyundai Pharmaceutical Co., LTD. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HD-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02378194 ↗ |
| Action | Inhibit | “found to inhibit the renal failure progression” NCT02378194 ↗ |
| Route | Oral | “24 weeks, once daily oral administration” NCT02378194 ↗ |